Drug Profile
GW 409544
Alternative Names: GW 409544X; GW 544Latest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Ligand Pharmaceuticals
- Developer GlaxoSmithKline
- Class Antihyperlipidaemics
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 01 May 2002 Discontinued - Phase-I for Hyperlipidaemia in United Kingdom (unspecified route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 07 Feb 2000 Phase-I clinical trials for Hyperlipidaemia in United Kingdom (Unknown route)